Melanoma Trial, Recruiting (NCT05570227)

Melanoma Trial, Recruiting NCT05570227 Sponsor: Peter MacCallum Cancer Centre, Australia Condition: Melanoma

Printed from Voxsanity (voxsanity.com.au) — NCT05570227 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Melanoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have given written consent to participate
People aged 18 years or older at the time of giving written consent
People who have a known melanoma lesion that a doctor has determined needs to be surgically removed or biopsied
People who are willing and able to follow the study procedures for the full duration of the trial, including having biopsies and, where applicable, receiving a special sugar (stable isotope) infusion

Who may not be able to join:

People who have diabetes mellitus
People who are pregnant or breastfeeding
People who, in the opinion of the study investigator, are unable to follow the study procedures and attend required follow-up appointments

Note: The exclusion criteria above specifically apply to those who would receive the [U-¹³C]Glucose (a type of labelled sugar) infusion as part of the study. If this infusion does not apply to a particular participant, these criteria may not be relevant — confirm with the trial site.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Aparna Rao, MBBS PhD, Peter MacCallum Cancer Centre, Australia

Phone: +61385595000

Australian sites

Peter Mac Callum Cancer Centre, Melbourne, Victoria

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05570227

Sponsor: Peter MacCallum Cancer Centre, Australia

Phase: Not Applicable

Status: Recruiting

Condition: Melanoma

Trial contact: +61385595000

More information: https://clinicaltrials.gov/study/NCT05570227

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have given written consent to participate
People aged 18 years or older at the time of giving written consent
People who have a known melanoma lesion that a doctor has determined needs to be surgically removed or biopsied
People who are willing and able to follow the study procedures for the full duration of the trial, including having biopsies and, where applicable, receiving a special sugar (stable isotope) infusion

Who may not be able to join:

People who have diabetes mellitus
People who are pregnant or breastfeeding
People who, in the opinion of the study investigator, are unable to follow the study procedures and attend required follow-up appointments

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Peter MacCallum Cancer Centre, Australia

Registry

ClinicalTrials.gov

Start date

27 June 2023

Est. completion

1 October 2027

Where this trial is recruiting

🇦🇺 Australia

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Glucose Utilisation in the TCA cycle; Lactate Utilisation in the TCA cycle

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov